Related Experiment Video
Updated: Jun 15, 2025
Ultrasonic-augmented Primary Adult Fibroblast Isolation
Published on: July 29, 2019
Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts
Abstract:
Fibrosis is a common outcome of numerous pathologies, including chronic kidney disease (CKD), a progressive renal function deterioration. Current approaches to target activated fibroblasts, key effector contributors to fibrotic tissue remodeling, lack specificity. Here, we report Gucy1α1 as a specific kidney fibroblast marker. Gucy1α1 levels significantly increased over the course of two clinically relevant murine CKD models and directly correlated with established fibrosis markers. Immunofluorescent (IF) imaging showed that Gucy1α1 comprehensively labelled cortical and medullary quiescent and activated fibroblasts in the control kidney and throughout injury progression, respectively. Unlike traditionally used markers platelet derived growth factor receptor beta (Pdgfrβ) and vimentin (Vim), Gucy1α1 did not overlap with off-target populations such as podocytes. Notably, Gucy1α1 labelled kidney fibroblasts in both male and female mice. Furthermore, we observed elevated GUCY1α1 expression in the human fibrotic kidney and lung. Studies in the murine models of cardiac and liver fibrosis revealed Gucy1α1 elevation in activated Pdgfrβ-, Vim- and alpha smooth muscle actin (αSma)-expressing fibroblasts paralleling injury progression and resolution. Overall, we demonstrate Gucy1α1 as an exclusive fibroblast marker in both sexes. Due to its multiorgan translational potential, GUCY1α1 might provide a novel promising strategy to specifically target and mechanistically examine fibroblasts.
Insights
Researchers identified Gucy1α1 as a specific marker for kidney fibroblasts, crucial in fibrotic diseases like chronic kidney disease (CKD). This discovery offers a precise way to target these cells in various fibrotic conditions.
Area of Science:
- Nephrology
- Fibrosis Research
- Cell Biology
Background:
- Fibrosis, a hallmark of chronic kidney disease (CKD), involves activated fibroblasts contributing to tissue remodeling.
- Current methods for targeting fibroblasts lack specificity, hindering effective treatment development.
Purpose of the Study:
- To identify and validate a specific marker for kidney fibroblasts.
- To assess the potential of this marker for diagnosing and targeting fibrotic diseases.
Main Methods:
- Utilized two clinically relevant murine CKD models.
- Performed immunofluorescent (IF) imaging to visualize marker expression.
- Validated findings in human fibrotic kidney and lung tissues, and murine cardiac and liver fibrosis models.
Main Results:
- Gucy1α1 was identified as a specific marker for quiescent and activated kidney fibroblasts in both sexes.
- Gucy1α1 levels correlated with fibrosis severity and did not overlap with non-fibroblast cell populations.
- Elevated GUCY1α1 expression was observed in human fibrotic kidneys and lungs, and in murine models of cardiac and liver fibrosis.
Conclusions:
- Gucy1α1 is a highly specific and broadly applicable fibroblast marker across multiple organs.
- GUCY1α1 presents a promising target for the specific examination and potential therapeutic targeting of fibroblasts in fibrotic diseases.
